AI Article Synopsis
- This study examines the impact of non-culprit plaques on long-term outcomes in patients with acute coronary syndrome (ACS), highlighting their significant role in future cardiovascular events.
- Out of 169 patients monitored for nearly 5 years, 24% experienced major adverse cardiovascular events unrelated to their initial heart attack, indicating the risks associated with non-culprit plaques.
- Key risk factors for these future events included the presence of obstructive non-culprit plaques, higher plaque burden, dyslipidaemia, and diabetes, with non-culprit plaques remaining an independent predictor of adverse outcomes in multivariate analysis.
Article Abstract
Aims: Non-culprit plaques are responsible for a substantial number of future events in patients with acute coronary syndrome (ACS). In this study, we evaluated the prognostic implications of non-culprit plaques seen on coronary computed tomography angiography (CTA) in patients with ACS.
Methods And Results: Coronary CTA was performed in 169 patients (mean 59 ± 11 years, 129 males) admitted with ACS. Data sets were assessed for the presence of obstructive non-culprit plaques (>50% luminal narrowing), segment involvement score, and quantitative measures of plaque burden, after censoring initial culprit plaques. Follow-up was performed for the occurrence of major adverse cardiovascular events (MACEs) unrelated to the initial culprit plaque; cardiac death, second ACS, or coronary revascularization after 90 days. After a median follow-up of 4.8 (IQR 2.6-6.6) years, MACE occurred in 36 (24%) patients: 6 cardiac deaths, 16 second ACS, and 14 coronary revascularizations. Dyslipidaemia (hazard ratio [HR] 3.1 [95% confidence interval 1.5-6.6]) and diabetes mellitus (HR 4.8 [2.3-10.3]) were univariable clinical predictors of MACE. Patients with remaining obstructive non-culprit plaques (HR 3.66 [1.52-8.80]) and higher plaque burden index (HR 1.22 [1.01-1.48]) had a more risk of MACE. In multivariate analysis, with diabetes, dyslipidaemia, and plaque burden index, obstructive non-culprit plaques (HR 3.76 [1.28-11.09]) remained an independent predictor of MACE.
Conclusion: Almost a quarter of the study population experienced a new event arising from a non-culprit plaque during a follow-up of almost 5 years. ACS patients with remaining obstructive non-culprit plaques or high plaque burden have an increased risk of future MACE.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ehjci/jeu111 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of adverse cardiovascular event endpoints between patients with diabetes and patients without diabetes based on coronary artery plaques: a systematic review and meta-analysis.
J Cardiothorac Surg
December 2024
Department of Medical Informatics, Medical School of Nantong University, Nantong, 226001, China.
Background: The classification of major adverse cardiovascular event (MACE) endpoints in patients with type 2 diabetes mellitus (T2DM) and either confirmed coronary artery disease (CAD) or high CAD risk, as well as the extent of the association between T2DM and coronary plaque characteristics, remains uncertain.
Purpose: This meta-analysis aims to compare MACE endpoints between patients with diabetes and patients without diabetes based on coronary artery plaques.
Methods: We searched studies from Web of Science, PubMed, Embase, and the Cochrane Library up until September 1, 2023.
Background: Embolic stroke of undetermined source (ESUS) may be associated with carotid artery plaques with <50% stenosis. Plaque vulnerability is multifactorial, possibly related to intraplaque hemorrhage (IPH), lipid-rich-necrotic-core (LRNC), perivascular adipose tissue (PVAT), and calcification morphology. Machine-learning (ML) approaches in plaque classification are increasingly popular but often limited in clinical interpretability by black-box nature.
View Article and Find Full Text PDFHigh-risk features in non-culprit lesions and clinical outcome after NSTEMI versus STEMI.
Eur Heart J Cardiovasc Imaging
November 2024
Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
Article Synopsis
- The study investigates the impact of non-culprit (NC) lesions in patients with NSTEMI compared to those with STEMI, focusing on high-risk plaque features and their influence on clinical outcomes.
- Among 438 patients, both NSTEMI and STEMI groups showed similar prevalence of high-risk plaques, but NSTEMI patients had a higher rate of major adverse cardiovascular events (MACE) after two years.
- The findings suggest that the presence of high-risk plaques in NC lesions is critical for dictating future cardiovascular events, indicating the need for further research on effective revascularization strategies in NSTEMI patients.
Functional and morphological improvement of significant non-culprit coronary artery stenosis by LDL-C reduction with a PCSK9 antibody: Rationale and design of the randomized FITTER trial.
Heliyon
October 2024
Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
Article Synopsis
- * Patients in the trial receive either evolocumab or a placebo for 12 weeks, alongside high-intensity statin therapy, and are monitored for changes in plaque size and composition using advanced imaging techniques.
- * This study is notable for being the first to assess how significant reductions in low-density lipoprotein cholesterol (LDL-C) could impact the health of non-critical coronary lesions shortly after treatment.
PCSK9 Inhibitors: Is the Time Ripe for the "Fast Track" Use Independently on the LDL-C Baseline Values in Acute Coronary Syndrome?
High Blood Press Cardiovasc Prev
November 2024
Dipartimento di Scienze Biomediche Avanzate, Università FEDERICO II, Via Pansini n.5, Napoli, 80131, Italy.
The low-density lipoprotein cholesterol (LDL-C) lowering decreases the risk to develop major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS). Therefore, the "fast track" use of PCSK9 inhibitors (PCSK9i) has been introduced in ACS patients not achieving LDL-C target (70 mg/dl) despite an ongoing lipid lowering therapy with statin at maximum tolerated dosage plus ezetimibe or stain-naïve (LDL-C > 130 mg/dl). PCSK9i "fast track" use has shown to achieve the regression of "non-culprit" atherosclerotic plaques leading to a further MACE decrease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!